BACKGROUND: Using our statin analysis method, it was possible to uncover a significant drop in statin levels (atorvastatin, simvastatin, and metabolites) after extracorporeal LDL-cholesterol elimination (EE) in severe familial hypercholesterolemia (FH). The purpose of this work was to identify the mechanism underlying this drop and its clinical significance as well as to propose measures to optimize a pharmacotherapeutical regimen that can prevent the loss of statins. METHODS: Ultra High Performance Liquid Chromatography (UHPLC) connected to the triple quadrupole MS/MS system was used. Patients. A group of long-term treated patients (3-12 years of treatment) with severe FH (12 patients) and treated regularly by LDL-apheresis (immunoadsorption) or haemorheopheresis (cascade filtration) were included in this study. RESULTS: After EE, the level of statins and their metabolites decreased (atorvastatin before/after LDL-apheresis: 8.83/3.46 nmol/l; before/after haemorheopheresis: 37.02/18.94 nmol/l). A specific loss was found (concentration of atorvastatin for LDL-apheresis/haemorheopheresis: 0.28/3.04 nmol/l in washing fluids; 11.07 nmol/l in filters). To prevent substantial loss of statin concentrations, a pharmacotherapeutic regimen with a longer time interval between the dose of statins and EE is recommended (15 hours). CONCLUSIONS: A specific loss of statins was found in adsorbent columns and filters. The decrease can be prevented by the suggested dosage scheme.

2nd Department of Internal Medicine Hematology Medical Faculty and Teaching Hospital Charles University Hradec Králové Czech Republic

Zobrazit více v PubMed

Thompsen J, Thompson PD. A systematic review of LDL apheresis in the treatment of cardiovascular disease. Atherosclerosis. 2006;189(1):31–38. PubMed

Borberg H. Quo vadis haemapheresis: current developments in haemapheresis. Transfusion and Apheresis Science. 2006;34(1):51–73. PubMed

Borberg H. 26 Years of LDL—apheresis: a review of experience. Transfusion and Apheresis Science. 2009;41(1):49–59. PubMed

Thompson GR. LDL apheresis. Atherosclerosis. 2003;167(1):1–13. PubMed

Thompson GR. Recommendations for the use of LDL apheresis. Atherosclerosis. 2008;198(2):247–255. PubMed

Klingel R, Fassbender T, Fassbender C, Göhlen B. From membrane differential filtration to lipidfiltration: technological progress in low-density lipoprotein apheresis. Therapeutic Apheresis. 2003;7(3):350–358. PubMed

Wlodarczyk J, Sullivan D, Smith M. Comparison of benefits and risk sof rosuvastatin versus atorvastatin from a meta-analysis of head-tohead randomized controlled trials. American Journal of Cardiology. 2008;102(12):1654–1662. PubMed

Yang D-J, Hwang LS. Study on the conversion of three natural statins from lactone forms to their corresponding hydroxy acid forms and their determination in Pu-Erh tea. Journal of Chromatography A. 2006;1119(1-2):277–284. PubMed

Bláha V, Solichová D, Zadák Z, et al. Imunoadsorption LDL-apheresis in the treatment of hypercholesterolemia: five years of research and clinical experience. Nutrition. 2002;18:p. 211.

Lins RL, Matthys KE, Verpooten GA, et al. Pharmacokinetics of atorvastatin and its metabolites after single and multiple dosing in hypercholesterolaemic haemodialysis patients. Nephrology Dialysis Transplantation. 2003;18(5):967–976. PubMed

Bellosta S, Paoletti R, Corsini A. Safety of statins: focus on clinical pharmacokinetics and drug interactions. Circulation. 2004;109(23):50–57. PubMed

Shitara Y, Sugiyama Y. Pharmacokinetic and pharmacodynamic alterations of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors: drug-drug interactions and interindividual differences in transporter and metabolic enzyme functions. Pharmacology and Therapeutics. 2006;112(1):71–105. PubMed

M. Sacks F. The relative role of low-density lipoprotein cholesterol and high-density lipoprotein cholesterol in coronary artery disease: evidence from large-scale statin and fibrate trials. American Journal of Cardiology. 2001;88(12A):14N–18N. PubMed

Bertolini S, Bon GB, Campbell LM, et al. Efficacy and safety of atorvastatin compared to pravastatin in patients with hypercholesterolemia. Atherosclerosis. 1997;130(1-2):191–197. PubMed

Horacek JM, Tichy M, Pudil R, et al. Multimarker approach to evaluation of cardiac toxicity during preparative regimen and hematopoietic cell transplantation. Neoplasma. 2008;55(6):532–537. PubMed

Horacek JM, Tichy M, Pudil R, Jebavy L. Glycogen phosphorylase BB could be a new circulating biomarker for detection of anthracycline cardiotoxicity. Annals of Oncology. 2008;19(9):1656–1657. PubMed

Šmahelová A, Hyšpler R, Haas T, Tichá A, Bláha V, Zadák Z. Effect of atorvastatin on non-cholesterol sterols in patients with type 2 diabetes mellitus and cardiovascular disease. Pharmacological Research. 2005;51(1):31–36. PubMed

Nakamura T, Sato E, Fujiwara N, et al. Co-administration of ezetimibe enhances proteinuria-lowering effects of pitavastatin in chronic kidney disease patients partly via a cholesterol-independent manner. Pharmacological Research. 2010;61(1):58–61. PubMed

Pastorini E, Rotini R, Guardigli M, et al. Development and validation of a HPLC-ES-MS/MS method for the determination of glucosamine in human synovial fluid. Journal of Pharmaceutical and Biomedical Analysis. 2009;50(5):1009–1014. PubMed

Lindegardh N, Tarning J, Toi PV, et al. Quantification of artemisinin in human plasma using liquid chromatography coupled to tandem mass spectrometry. Journal of Pharmaceutical and Biomedical Analysis. 2009;49(3):768–773. PubMed PMC

Bullen WW, Miller RA, Hayes RN. Development and validation of a high-performance liquid chromatography tandem mass spectrometry assay for atorvastatin, ortho-hydroxy atorvastatin, and para-hydroxy atorvastatin in human, dog, and rat plasma. Journal of the American Society for Mass Spectrometry. 1999;10(1):55–66. PubMed

Lee J-H, Woo Y-A, Hwang I-C, et al. Quantification of CKD-501, lobeglitazone, in rat plasma using a liquid-chromatography/tandem mass spectrometry method and its applications to pharmacokinetic studies. Journal of Pharmaceutical and Biomedical Analysis. 2009;50(5):872–877. PubMed

Bláha M, Cermanová M, Bláha V, et al. Safety and tolerability of long lasting LDL-apheresis in familial hyperlipoproteinemia. Therapeutic Apheresis and Dialysis. 2007;11(1):9–15. PubMed

Bláha M, Krejsek J, Andrýs C, et al. Adhesive selectin molecules, MCP-1 and endotelin-1 during long-lasting LDL apheresis in familial hyperlipoproteinemia. Therapeutic Apheresis and Dialysis. 2005;9(A29) PubMed

Bláha M, Strasova A, Ungerman L, et al. Significance of non-invasive cardiovascular examinations for the evaluation of extracorporeal LDL-cholesterol elimination efficacy. Transfusion Medicine and Hemotherapy. 2008;35, supplement:p. 80.

Bláha M, Rencová E, Studnička J, et al. Cascade filtration in the therapy of the dry form of age-related macular degeneration. Therapeutic Apheresis and Dialysis. 2009;13(5):453–454. PubMed

Nováková L, Vlčková H, Šatínský D, et al. Ultra high performance liquid chromatography tandem mass spectrometric detection in clinical analysis of simvastatin and atorvastatin. Journal of Chromatography B. 2009;877(22):2093–2103. PubMed

Williams RR, Hunt SC, Schumacher MC, et al. Diagnosing heterozygous familial hypercholesterolemia using new practical criteria validated by molecular genetics. American Journal of Cardiology. 1993;72(2):171–176. PubMed

Samánek M, Urbanová Z. Cholesterol and triglyceride levels and their development from 2 to 17 years of age. Casopís Lékarů Ceských. 1997;136(12):380–385. PubMed

Sleator RD, Hill C. Rational design of improved pharmabiotics. Journal of Biomedicine and Biotechnology. 2009;2009:7 pages. Article ID 275287. PubMed PMC

Ye L-H, Zhang H, Wu L-Y, et al. Anti-Hepatitis B Virus X protein in sera is one of the markers of development of liver cirrhosis and liver cancer mediated by HBV. Journal of Biomedicine and Biotechnology. 2009;2009:6 pages. Article ID 289068. PubMed PMC

Karray-Chouayekh S, Trifa F, Khabir A, et al. Clinical significance of epigenetic inactivation of hMLH1 and BRCA1 in tunisian patients with invasive breast carcinoma. Journal of Biomedicine and Biotechnology. 2009;2009:7 pages. Article ID 369129. PubMed PMC

Iga AM, Robertson JHP, Winslet MC, Seifalian AM. Clinical potential of quantum dots. Journal of Biomedicine and Biotechnology. 2007;2007:10 pages. Article ID 76087. PubMed PMC

El Andaloussi A, Bilhou-Nabera C. New complex chromosomal translocation in chronic myeloid leukaemia: T(9;18;22)(q34;p11;q11) Journal of Biomedicine and Biotechnology. 2007;2007:3 pages. Article ID 92385. PubMed PMC

Stern RH, Yang B-B, Hounslow NJ, Macmahon M, Abel RB, Olson SC. Pharmacodynamics and pharmacokinetic-pharmacodynamic relationships of atovarstatin, an HMG-CoA reductase inhibitor. Journal of Clinical Pharmacology. 2000;40(6):616–623. PubMed

Rossi J, Jonak P, Rouleau L, Danielczak L, Tardif J-C, Leask RL. Differential response of endothelial cells to Simvastatin when conditioned with steady, non-reversing pulsatile or oscillating shear stress. Annals of Biomedical Engineering. In press. PubMed

Heeschen C, Hamm CW, Laufs U, Snapinn S, Böhm M, White HD. Withdrawal of statins increases event rates in patients with acute coronary syndromes. Circulation. 2002;105(12):1446–1452. PubMed

Wanahita N, Chen J, Bangalore S, et al. The effect of statin therapy on ventricular tachyarrhythmias: a meta-analysis. American Journal of Therapeutics. In press. PubMed

Zoja C, Corna D, Gagliardini E, et al. Adding a statin to a combination of ACE inhibitor and ARB normalizes proteinuria in experimental diabetes which translates into full renoprotection. American Journal of Physiology. In press. PubMed

Rosenson RS, Tangney CC. Antiatherothrombotic properties of statins: implications for cardiovascular event reduction. Journal of the American Medical Association. 1998;279(20):1643–1650. PubMed

Goodman & Gilman’s. The Pharmacological Basis of Therapeutics. 11th edition. New York, NY, USA: McGraw-Hill; 2006.

Sweetman SC. Martindale: The Complete Drug Reference. 35th edition. London, UK: Pharmaceutical Press; 2007.